Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
EuroAPI set to double capacity for prostaglandin in Budapest
by Rick Mullin
June 9, 2023
| A version of this story appeared in
Volume 101, Issue 19
EuroAPI plans to invest $54 million in a new manufacturing facility at its plant in Budapest, Hungary. The two-phase project is designed to more than double prostaglandin production capacity at the site by 2027. EuroAPI, the world’s leading supplier of large-scale commercial prostaglandins, halted production at the plant in November after identifying deficiencies in documentation management. It began restarting operations in January. The company estimates 5–7% growth in the market for prostaglandin between 2022 and 2027.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter